Author + information
Previous studies showed admission levels of hemoglobin A1c (HbA1c) correlate with long-term outcomes in patients with bare metal stents. It is uncertain that HbA1c is associated with an increased risk of cardiovascular events in patients undergoing DES.
Methods and Results
This study compared the impact of HbA1c on clinical outcomes of BMS and DES in a single-center prospective registry. This was an observational study of 3,492 consecutive patients who underwent PCI between 2000 and 2011. Of the 3492 consecutive patients, 1897 patients received BMS, and the remaining 1,595 patients received DES. Patients were assigned to four groups according to the quadrant values of admission HbA1c. The primary endpoint was composite of MACE (all-cause death, ACS and revascularization). The mean follow-up duration was 4.5 years. As figured showed, the higher the HbA1c, the higher the rate of MACE and ASC plus death (p<.0001, 0.002) in the BMS group. However, HbA1c showed no such correlation with MACE and ACS plus death (p = 0.20, 0.69) in the DES group. Multivariable Cox regression analysis showed that HbA1c was not associated with long-term outcomes in DES.
HbA1c has no impact on long-term outcomes of patients implanted with DES. In contrast, HbA1c correlates with higher MACE rates in BMS group.